{"schema_version":"secwatch.filing_event.v1","accession":"0001821586-25-000009","form_type":"8-K","ticker":"MLTX","cik":"0001821586","company_name":"MoonLake Immunotherapeutics","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.926671+00:00","generated_at":"2026-05-22T00:16:52.456394+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MoonLake reports Q1 2025 cash of $480.1M, secures up to $500M debt facility; Phase 3 HS enrollment complete","bullets":["Cash, cash equivalents and short-term marketable debt securities of $480.1M as of March 31, 2025.","Up to $500M non-dilutive debt facility with Hercules Capital; $75M drawn at close, extends cash runway into 2028.","Phase 3 VELA program in hidradenitis suppurativa fully enrolled; top-line results expected around September 2025.","R&D expenses $36.5M (similar to prior quarter); G&A expenses $11.0M (up from $9.2M).","Interim readout of Phase 2 LEDA trial in palmoplantar pustulosis presented; primary endpoint readout expected 2H 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001821586-25-000009","json":"https://secwatch.observer/filing/0001821586-25-000009.json","markdown":"https://secwatch.observer/filing/0001821586-25-000009.md","text":"https://secwatch.observer/filing/0001821586-25-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821586/000182158625000009/0001821586-25-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821586/000182158625000009/mnlk-20250512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T00:16:52.456394+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}